Streamlining Dupixent CGM Prior Auth: A Unified Approach to Complex PAs
Navigating the complexities of prior authorizations for both high-cost specialty medications like Dupixent and essential medical devices such as continuous glucose monitors (CGM) requires a unified strategy. Klivira provides the automation needed to streamline Dupixent CGM prior auth workflows, ensuring efficiency across diverse benefit types.
Revenue cycle directors and prior authorization coordinators face increasing pressure to manage disparate PA requirements for a single patient's care. When patients require both pharmacy-benefit specialty drugs like Dupixent (dupilumab) and medical-benefit devices like CGMs, the administrative load intensifies. Klivira addresses this challenge by integrating and automating these distinct prior authorization pathways.
Understanding Dupixent Prior Authorization Dynamics
Dupixent, an IL-4/IL-13 inhibitor, is a high-volume prior authorization target due to its specialty drug classification and cost. Authorizations for Dupixent typically fall under the pharmacy benefit, requiring adherence to specific payer formularies, step-therapy protocols, and often routing through specialty pharmacies. Efficient ePA submission via NCPDP SCRIPT standards is critical for these high-touch medications.
Navigating Continuous Glucose Monitor (CGM) Prior Auth Workflows
Continuous glucose monitors, including devices like Dexcom and Libre, typically require prior authorization under the medical benefit. These authorizations often involve documentation of specific diabetes types, insulin dependence, and A1C levels. Beyond initial CGM authorization, health systems must also manage recurrent supply re-authorization workflows, which can be a significant administrative burden without automation.
The Intersection: Managing Pharmacy and Medical Benefit PAs Simultaneously
The true challenge arises when a patient requires both a specialty medication like Dupixent and a device like a CGM. This necessitates managing separate prior authorization processes, often with different payer portals, documentation requirements, and benefit pathways (e.g., medical vs. pharmacy). Klivira's platform is engineered to handle this complexity, providing a centralized system for diverse PA submissions, regardless of benefit type or specific workflow.
Key Documentation for Dupixent and CGM Prior Authorizations
- **For Dupixent (dupilumab):** Confirmed diagnosis for an FDA-approved indication (e.g., atopic dermatitis, asthma, EoE, CRSwNP), documentation of failed prior therapies (step-therapy adherence), and physician attestation of medical necessity.
- **For CGM (Dexcom, Libre):** Diagnosis of diabetes (Type 1 or Type 2), documentation of insulin use (multiple daily injections or insulin pump), history of glucose monitoring, and attestation of medical necessity for continuous monitoring.
- Payer-specific forms and clinical criteria, often requiring detailed patient history and lab results.
- Appeals documentation for initial denials, including clinical rationale for exception requests.
Leveraging Klivira for Integrated PA Management
Klivira's platform integrates with EMRs and payer portals, supporting both X12 278 (for medical benefit PAs like CGM) and NCPDP SCRIPT (for pharmacy benefit PAs like Dupixent). Our system automates data extraction, intelligent form completion, and submission tracking, reducing manual effort and potential for errors. This unified approach ensures that whether you're processing a Dupixent ePA or a CGM re-authorization, your team operates with maximum efficiency.
Frequently asked questions
What are the primary differences in PA requirements for Dupixent versus CGMs?
Dupixent typically falls under the pharmacy benefit and requires ePA submission via NCPDP SCRIPT, often involving specialty pharmacy coordination and step-therapy protocols. CGMs, conversely, are usually covered under the medical benefit, utilizing X12 278 transactions, and require documentation of diabetes type, insulin use, and medical necessity for a device.
How does Klivira handle the diverse documentation needs for these distinct prior authorizations?
Klivira's platform extracts relevant clinical data directly from the EMR, intelligently populating payer-specific forms for both Dupixent (e.g., diagnosis, failed therapies) and CGM (e.g., diabetes type, insulin regimen, A1C). This automation ensures accurate and complete submissions across varied requirements, minimizing manual data entry and improving approval rates.
Can Klivira manage both initial CGM authorizations and subsequent supply re-authorizations?
Yes, Klivira is designed to manage the full lifecycle of prior authorizations, including initial CGM authorizations and recurring supply re-authorizations. Our system tracks authorization expiry dates and proactively initiates renewal workflows, ensuring continuity of care and preventing unnecessary service disruptions for patients.
What role do ePA standards like NCPDP SCRIPT and X12 278 play in this combined workflow?
NCPDP SCRIPT is vital for pharmacy benefit PAs like Dupixent, facilitating electronic submission to PBMs and specialty pharmacies. X12 278 is the standard for medical benefit PAs, used for devices like CGMs. Klivira supports both standards, providing a comprehensive solution for electronic prior authorization regardless of the benefit type, streamlining communication with payers.
Related coverage
Ready to automate this workflow?
See how Klivira automates prior authorizations for your team.
Request a demo